Hans Popper State of the Art: Next Generation Human Liver Gene Therapy

Description

Presenter: Holger Willenbring, MD, PhD

Human liver gene therapy with AAV vectors has reached a pivotal stage, marked by the first FDA approval but also fatalities from liver toxicity. Realizing its potential requires transducing hepatocytes or other therapeutically relevant cells in the human liver with maximum efficiency and specificity.